New hope for lung disease patients: inhaled drug shows promise in long-term safety trial
NCT ID NCT07234032
First seen Nov 18, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study looks at the long-term safety of an inhaled medication called treprostinil palmitil inhalation powder (TPIP) for people with pulmonary hypertension caused by interstitial lung disease. About 344 adults who finished a previous study will take the drug and be monitored for side effects and changes in walking distance and lung function. The goal is to see if TPIP is safe and tolerable over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.